CBIO · Company research
Crescent Biopharma, Inc. (CBIO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| More than 125 patients have received an experimental cancer drug. It’s now being tested with chemotherapy. - Stock Titan | More than 125 patients have received an experimental cancer drug. It’s now being tested with chemotherapy. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 15, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma, Inc. (CBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada | Crescent Biopharma, Inc. (CBIO) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Six employees can buy Crescent shares for $13.94 each once their options vest. - Stock Titan | Six employees can buy Crescent shares for $13.94 each once their options vest. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| The FDA clears an application to test Crescent’s cancer treatment in people. - Stock Titan | The FDA clears an application to test Crescent’s cancer treatment in people. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| GlycoMimetics, the company behind GlycoMimetics stock, changes ticker to CBIO - ad-hoc-news.de | GlycoMimetics, the company behind GlycoMimetics stock, changes ticker to CBIO ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 1, 2026 | neutral | 0 | 0.6 |
| Two Crescent employees received rights to buy 31,200 shares at $14.24 each - Stock Titan | Two Crescent employees received rights to buy 31,200 shares at $14.24 each Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| $CBIO stock is down 14% today. Here's what we see in our data. - Quiver Quantitative | $CBIO stock is down 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 23, 2026 | neutral | 0 | 0.6 |
| $CBIO stock is down 14% today. Here's what we see in our data. - Quiver Quantitative | $CBIO stock is down 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 23, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma (NASDAQ: CBIO) CFO offloads 568 shares - Stock Titan | Crescent Biopharma (NASDAQ: CBIO) CFO offloads 568 shares Stock Titan | View source ↗ | Stock Titan | Sep 18, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma (CBIO) insider sale covers taxes - Stock Titan | Crescent Biopharma (CBIO) insider sale covers taxes Stock Titan | View source ↗ | Stock Titan | Sep 18, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma (CBIO) CEO’s stock sale tied to tax withholding plan - Stock Titan | Crescent Biopharma (CBIO) CEO’s stock sale tied to tax withholding plan Stock Titan | View source ↗ | Stock Titan | Sep 18, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma (CBIO) legal chief sells shares to cover RSU taxes - Stock Titan | Crescent Biopharma (CBIO) legal chief sells shares to cover RSU taxes Stock Titan | View source ↗ | Stock Titan | Sep 18, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma (NASDAQ: CBIO) holder plans 16,775-share Rule 144 sale after recent trades - Stock Titan | Crescent Biopharma (NASDAQ: CBIO) holder plans 16,775-share Rule 144 sale after recent trades Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| $CBIO stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $CBIO stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 31, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support Level - Low Risk Entry Stocks - dars.gov.et | Crescent Biopharma (CBIO) Shares Dip 2.86% as Stock Approaches Key $16 Support Level - Low Risk Entry Stocks dars.gov.et | View source ↗ | dars.gov.et | Aug 11, 2026 | neutral | 0 | 0.6 |
| Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) - The Globe and Mail | Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) The Globe and Mail | View source ↗ | The Globe and Mail | May 1, 2026 | neutral | 0 | 0.6 |
| Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis | Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree Trefis | View source ↗ | Trefis | Apr 3, 2026 | neutral | 0 | 0.6 |
| The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today - Stocktwits | The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today Stocktwits | View source ↗ | Stocktwits | Dec 4, 2025 | neutral | 0 | 0.6 |
| Crescent Biopharma (Nasdaq:CBIO) - Stock Analysis - Simply Wall Street | Crescent Biopharma (Nasdaq:CBIO) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Jun 20, 2025 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.